← SynDRA
BUSULFAN
SynDRA canonical compound SYN0002037 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Mechanism of action | DNA inhibitor |
|---|
| Indication | chronic myeloid leukemia (CML) |
|---|
| Disease area | hematologic malignancy |
|---|
All known targets
Mechanisms of action (all sources)
Drug classes
- Alkylating Activity
- Alkylating Drug
- Alkylating Agents
- Antineoplastic Agents
- Antineoplastic Agents, Alkylating
- Immunologic Factors
- Immunosuppressive Agents
- Myeloablative Agonists
- Noxae
ATC classes
Cross-references
Synonyms
- busilvex
- busulfex
- busulphan
- citosulfan
- glyzophrol
- leucosulfan
- sulphabutin
- Busulfano
- Busulfanum
- Leucosulfan
- Myelosan
- Myelosanum
- Sulphabutin
- NCI-C01592
- NSC-750
- Busilvex
- Busulfan fresenius kabi
- Busulfex
- Myleran
- Busulphan
- Busulphane
- Butanedioldimethanesulfonate
- Buzulfan
- Citosulfan
- Glyzophrol
- Mablin
- Methanesulfonic
- Mielevcin
- Mielosan
- Mielucin
- Milecitan
- Mileran
- Misulban
- Mitosan
- Mitostan
- Myeleukon
- Myeloleukon
- Mylecytan
Reported adverse events
- Cataract
- Infection
- Myelosuppression
- Pneumonia
- Rash
- Seizure
- Cardiac tamponade
Look up BUSULFAN in the interactive SynDRA portal →